Bausch & Lomb BLCO
Bausch & Lomb Corp · NYSE · Ophthalmic Goods
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Aug. 10, 2026 | Frederick Munsch SVP, Controller and CAO | Sold | 52,900 | $16.78 | $887,662 |
| Aug. 7, 2026 | Andrew C. Von Eschenbach director | Sold | 6,059 | $16.58 | $100,458 |
| Aug. 6, 2026 | Andrew C. Von Eschenbach director | Sold | 12,500 | $16.50 | $206,250 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 20 →Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedBausch + Lomb Q3 2026 adjusted EPS of $0.34 beats $0.22 consensus; revenue $1.375 billion; full-year revenue and adjusted EBITDA guidance raised
Departure/appointment of directors or officers
AI summary, unreviewedBausch + Lomb director Nathalie Bernier resigns from board and science and technology committee; board does not plan to fill vacancy
Departure/appointment of directors or officers · Regulation FD disclosure · Financial statements and exhibits